Although it is still unclear whether the suppressive effects of activated Tregs contribute to the action of expressed IL-IR2 or the original functions of the Tregs themselves, IL-1R2+ CD4+ T cells and activated Tregs might be new targets for therapeutic intervention in IL-1-mediated neurodegenerative diseases. The gene discussed is IL1B; the disease is neurodegenerative disease.